drugset / Trial / NCT00416182
Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
RandomizedParallel-groupTriple-blindTreatment
Summary
Chronic sinusitis is a frequent complication in cystic fibrosis. The aim of this study is to determine whether Pulmozyme(dornase alfa) would maintain sinus health (compared to placebo) in patients with cystic fibrosis who have recently undergone sinus surgery.
Timeline
- Start
- 2006-12
- Primary completion
- 2012-06
- Completion
- 2012-06
Publications
- Results Lahiri T, Herrington H, Diehl S, Landrigan G. The effect of intranasal dornase alfa on chronic sinusitis in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol S35:354, 2012.
- Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD001127. doi: 10.1002/14651858.CD001127.pub5.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dornase alfa | Protein / enzyme biologic | 2.5 mg | Intranasal |
| Subject | dornase alfa | Protein / enzyme biologic | 2.5 ml | Intranasal |